0.01Open0.01Pre Close0 Volume154 Open Interest0.50Strike Price0.00Turnover425.43%IV48.91%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0468Delta0.2267Gamma95.99Leverage Ratio-0.0048Theta0.0000Rho-4.50Eff Leverage0.0001Vega
Veru Inc Stock Discussion
and 102 000 share to FISCH HARRY
Veru Reports Fiscal 2024 Second Quarter Financial Results and
Progress of its Enobosarm High Quality Weight Loss Clinical Program
—Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for highquality weight loss is actively enrolling—
—Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDswith significant relevant medical, clinical and scientific expertise—
—Company to present this month at upcoming American Ass...
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.
Presentation details:
Advanc...
No comment yet